HK1132461A1 - Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy - Google Patents

Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy

Info

Publication number
HK1132461A1
HK1132461A1 HK10100087.2A HK10100087A HK1132461A1 HK 1132461 A1 HK1132461 A1 HK 1132461A1 HK 10100087 A HK10100087 A HK 10100087A HK 1132461 A1 HK1132461 A1 HK 1132461A1
Authority
HK
Hong Kong
Prior art keywords
csf
agent
peripheral neuropathy
prevention
diabetic peripheral
Prior art date
Application number
HK10100087.2A
Other languages
English (en)
Inventor
Kyung-Soo Kim
Ji-Yong Jin
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of HK1132461A1 publication Critical patent/HK1132461A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK10100087.2A 2006-10-30 2010-01-06 Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy HK1132461A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060105684A KR100812274B1 (ko) 2006-10-30 2006-10-30 Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제
PCT/KR2007/005353 WO2008054098A1 (en) 2006-10-30 2007-10-29 Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy

Publications (1)

Publication Number Publication Date
HK1132461A1 true HK1132461A1 (en) 2010-02-26

Family

ID=39344418

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10100087.2A HK1132461A1 (en) 2006-10-30 2010-01-06 Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy

Country Status (16)

Country Link
US (2) US20100048869A1 (xx)
EP (1) EP2077852B1 (xx)
JP (1) JP5416589B2 (xx)
KR (1) KR100812274B1 (xx)
CN (1) CN101528251B (xx)
AU (1) AU2007314854B2 (xx)
BR (1) BRPI0718099A2 (xx)
CA (1) CA2667178C (xx)
ES (1) ES2448837T3 (xx)
HK (1) HK1132461A1 (xx)
MX (1) MX2009004646A (xx)
NZ (1) NZ576498A (xx)
PT (1) PT2077852E (xx)
RU (1) RU2448726C2 (xx)
UA (1) UA93581C2 (xx)
WO (1) WO2008054098A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100908628B1 (ko) * 2008-03-21 2009-07-21 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 외상성 말초신경 손상 치료용 조성물
KR20100020125A (ko) * 2008-08-12 2010-02-22 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 신경병증성 통증 예방 또는치료제
KR101032307B1 (ko) 2008-10-02 2011-05-06 전북대학교병원 생체적합성 분자광학영상용 양자점 및 이의 제조방법
CN114828890A (zh) * 2019-10-18 2022-07-29 比奥兹普科德公司 使用了干细胞迁移剂的糖尿病治疗
CN117750976A (zh) * 2021-02-26 2024-03-22 比奥兹普科德公司 用于糖尿病以及并发病的新型治疗、诊断和检测的方法以及制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202117A (en) * 1988-08-24 1993-04-13 Koichiro Tsuji Method of treating thrombi with g-csf
JP3954004B2 (ja) * 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
JPH0741429A (ja) * 1993-07-30 1995-02-10 Mitsubishi Chem Corp 神経障害改善薬
JP2003113085A (ja) * 1998-04-23 2003-04-18 Takeda Chem Ind Ltd 神経栄養因子様作用剤
AU782819B2 (en) * 1999-04-15 2005-09-01 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
DK1129720T3 (da) * 2000-02-29 2004-09-27 Pfizer Prod Inc Stabiliseret granulocyt-kolonistimulerende faktor
MXPA04002099A (es) * 2001-09-05 2004-06-07 Yamasa Corp Composiciones medicinales para neuropatia diabetica.
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004091661A1 (ja) * 2003-04-15 2004-10-28 Chugai Seiyaku Kabushiki Kaisha 糖尿病治療剤
CN1321640C (zh) * 2005-09-08 2007-06-20 南京医科大学 苄达赖氨酸在制备治疗糖尿病周围神经病变药物中的应用

Also Published As

Publication number Publication date
US20110076247A1 (en) 2011-03-31
BRPI0718099A2 (pt) 2013-11-05
CA2667178C (en) 2015-12-29
US20100048869A1 (en) 2010-02-25
KR100812274B1 (ko) 2008-03-13
WO2008054098A1 (en) 2008-05-08
AU2007314854B2 (en) 2014-01-16
JP2010508265A (ja) 2010-03-18
CA2667178A1 (en) 2008-05-08
PT2077852E (pt) 2014-03-04
ES2448837T3 (es) 2014-03-17
EP2077852A4 (en) 2012-01-18
JP5416589B2 (ja) 2014-02-12
AU2007314854A1 (en) 2008-05-08
NZ576498A (en) 2012-03-30
EP2077852A1 (en) 2009-07-15
CN101528251A (zh) 2009-09-09
CN101528251B (zh) 2013-03-06
EP2077852B1 (en) 2013-11-27
RU2009116833A (ru) 2010-12-10
MX2009004646A (es) 2009-05-22
UA93581C2 (ru) 2011-02-25
RU2448726C2 (ru) 2012-04-27

Similar Documents

Publication Publication Date Title
WO2007089454A3 (en) Methods for enhancing skin treatments
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
WO2007041398A3 (en) Treatment of cancer with specific rxr agonists
EA200870088A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови
EP2133365A3 (en) Compositions and methods for the treatment of infections and tumors
SG161259A1 (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2007100675A3 (en) Collagenase for treating cellulite
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX365007B (es) Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
HK1132461A1 (en) Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy
MX2022005303A (es) Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurologicas.
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
TW200833345A (en) Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues
MX2007001206A (es) Metodos para tratar la piel para mejorar el tratamiento terapeutico de la misma.
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
WO2008099804A1 (ja) 糖尿病白内障の治療剤
WO2006020912A3 (en) Treatments for congestive heart failure
WO2009116836A3 (en) Agent comprising g-csf for treatment of traumatic peripheral nerve injury and method for treating traumatic peripheral nerve injury with the same
WO2008020962A3 (en) Cholesterol lowering drug combination
PL2066409T3 (pl) Zastosowanie ekstraktu z quinoa jako kosmetycznego i farmaceutycznego środka czynnego odchudzającego i/lub jako środka czynnego zapobiegającego tworzeniu się nowych tłuszczów w ludzkim ciele

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171029